Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Forbedret behandling af patienter med langvarig opioidbehandling til ikke-kræftsmerter i primærpleje (Opi-Prim)

25. september 2026 opdateret af: Thomas Kempen, Uppsala County Council, Sweden

Forbedret behandling af patienter med langvarig opioidbehandling til ikke-kræftsmerter i primærpleje (OPI-prim)

The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:

What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?

Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.

Participants will receive a person-centred team-based treatment consisting of:

  • Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
  • Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
  • Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.

Primary objective:

To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care

Trial design and setting:

This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).

This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.

Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

110

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Gävleborg County
      • Gävle, Gävleborg County, Sverige
        • Ikke rekrutterer endnu
        • Region Gävleborg
        • Kontakt:
    • Södermanland County
      • Strängnäs, Södermanland County, Sverige
        • Ikke rekrutterer endnu
        • Region Sörmland
        • Kontakt:
    • Uppsala County
      • Uppsala, Uppsala County, Sverige
        • Rekruttering
        • Region Uppsala
        • Kontakt:
    • Örebro County
      • Örebro, Örebro County, Sverige

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
  • Able to speak Swedish or English

Exclusion Criteria:

  • Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
  • No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
  • Using their opioids for cancer pain

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Control

Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care.

Aktiv komparator: Intervention

Phase 1 (investigation and assessment, week 1-3):

  • A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
  • A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
  • A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
  • A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
  • A visit to a care manager

Phase 2 (treatment plan, week 3-4):

- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

  • Implementation of the individualized rehabilitation plan.
  • Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
  • A second team consultation half-way

Phase 1 (investigation and assessment, week 1-3):

  • A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
  • A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
  • A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
  • A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
  • A visit to a care manager

Phase 2 (treatment plan, week 3-4):

- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

  • Implementation of the individualized rehabilitation plan.
  • Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
  • A second team consultation half-way

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pain interference
Tidsramme: The primary outcome measure will be the difference in mean pain interference after 6 months.

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

The primary outcome measure will be the difference in mean pain interference after 6 months.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pain intensity
Tidsramme: After 3, 6 and 12 months

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse

After 3, 6 and 12 months
Symptoms of depression
Tidsramme: After 3, 6 and 12 months

Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse

After 3, 6 and 12 months
Symptoms of anxiety
Tidsramme: After 3, 6 and 12 months

Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse

After 3, 6 and 12 months
Patient satisfaction
Tidsramme: After 3, 6 and 12 months

Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse

After 3, 6 and 12 months
Quality of life according to the 5-level EuroQol 5D
Tidsramme: After 3, 6 and 12 months

Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse.

After 3, 6 and 12 months
Opioid use
Tidsramme: After 3, 6 and 12 months

Measured with as morphine equivalents: in mg.

After 3, 6 and 12 months
Symptoms of withdrawal
Tidsramme: After 3, 6 and 12 months

Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse

After 3, 6 and 12 months
Pain interference
Tidsramme: After 3 and 12 months

Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

After 3 and 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. marts 2025

Primær færdiggørelse (Anslået)

30. juni 2028

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

26. februar 2025

Først indsendt, der opfyldte QC-kriterier

26. februar 2025

Først opslået (Faktiske)

4. marts 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • Opi-Prim

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .